Shatter, named for its often peanut brittle-like texture and tendency to break into glass-like shards, is a concentrated derivative of marijuana. It has a THC (tetrahydrocannabinol) level of between 70 and 99 per cent.
$50 gr , 2 gr. for $90 and 3 gr. for $120
One of the best and most popular sativa,
This jack max puts you in a creative and euphoric mood.
326 East Hastings
How do you like it ?
Only $25 gr. , 1/8 for $80 and 1/4 for $150
Hashish, often known as hash or hashish oil (BHO), is a cannabis product composed of compressed or purified preparations of stalked resin glands, called trichomes. It contains the same active ingredients—such as THC and other cannabinoids—but often in higher concentrations than unsifted buds or leaves.
All $14 and $12 strains have been tagged $10 for today dec 26th ,
also the Death bubba budder is at $35 a gr. instead of $50.
and all our shatter at $40 gr instead of $50.. only at 45 west broadway location.
we accept other membership.
Hurry up this will be gone tomorrow.
Death Bubba oil is back .. 1 gr .. 1.2 gr.. and 1.5 gr.. starting at $25
Million people suffer from insomnia, insufficient sleep or another sleep disorder. CBD has been mistakenly described as sedating. In modest doses, CBD is mildly alerting. Cannabidiol activates the same adenosine receptors as caffeine, a stimulant. But several patients with sleep issues report that ingesting a CBD-rich tincture or extract a few hours before bedtime has a balancing effect that facilitates a good night’s sleep.
Shatter is smooth, clear and solid. It is the purest and most potent form because it involves a second extraction process that removes fats, lipids and waxes. This can result in over 80 percent THC.
Wednesday big Day,
all concentrates $40 gr.
and all $12 and $14 strains at $10 prices
326 East Hastings St.
Vancouver, BC V6A 1P4
Port Alberni location
3092 3rd Ave
Port Alberni, BC V9Y 2A5
10 am to 8 pm
Monday and Tuesday 3 joints for $5
Wednesday big Day, Budshake $1,
all concentrates $40 gr.
and all $12 and $14 strains at $10 prices
Thursday and Sunday hash $10 gr. instead of $15
Friday all $12 and $14 strains at $10 prices
Saturday all concentrates $40 gr.
Silver Haze was the first seed strain to deliver the full-strength Haze
experience in a fatter, faster, more compact form. Crossing Haze with a non-dominant indica Northern Lights, Silver Haze maintains strong but clear-headed sativa effects. Introduced by Sensi Seeds, the Silver Haze gets its name from the massive amount of shiny THC glands
covering the buds, sticky sativa blend that boasts an energetic, long-lasting body
The uplifting effects are a great remedy for
high stress levels or when suffering from a lack of appetite or nausea.
$3 - $4 - $5
Nice, Clean and Professional environment.
Limelife is proud to bring in services by helping and guiding all patients to the product that will meet their needs.
We have quality flowers and affordable medicine like a wide variety of cannabis products.
''You want me to put that
This is a common reaction to the suggestion that cannabis can be used as a suppository. Rectal administrations (suppositories) have an unfairly bad reputation
in North America, despite the diverse benefits they offer. This article aims to educate about the advantages associated with the rectal application of cannabis and provide a simple set of
guidelines for the effective use of suppositories.
The sweet flavors of
fresh blueberries combine
with relaxing effects to produce a long-lasting
sense of euphoria. Many medical patients appreciate
Blueberry for its ability to suppress pain and relieve stress, while connoisseurs and growers admire the strain for
its colorful hues and high THC content.
$4 - Lemon Kush
$5 - Violator, Girl Scout, Rockstar
$6 - Death Bubba, ,Pink Diamond, XXX
2 strains at $5, 1 strain at $6 and 1 strain at $7,50
CBD cap 40 MG.3$/ea.
2 for $5 or 20 for $40
CBD Concentrate $70
CBD : 200 mg THC : 0.10 mg
CBD :5.5 ml contain 25 ml
CBD Tincture (oil base)$45
CBD :5.5 ml contain 25 ml
CBD/THC Suppository $15 each
CBD: 60 mg THC: 60mg
Regular price 14$ gr. but today Nov 25th get it for $12/gr.
Black Diamond is a Northern California strain ideal for patients who need strong medication but still want to be active and sociable. A cross between and , its flowers have a glittery trichome covering and purple coloring that make it a beautiful gem to look at. The strain’s aroma is musky and earthy, almost like a deep red wine. Black Diamond is known to cause fits of giggles and is a great strain for hanging out with friends or catching up on TV shows at home. This strain tends to make consumers extremely hungry, making it a good choice for those looking to increase their appetite
sure you have some snacks on hand).
Monday- Tuesday - 3 for $5 joints
Wednesday an Saturday- all concentrates $45/g
Thursday an Sunday - $10 / g hash
and on Friday all Flowers at 10$/gr.
New Strains to Try.. watch our full and updated menu Online http://limelifesociety.com/nicol
Flowers starting a $5 , Bath bomb at $10 , 3 strains of shatter.. watch more
Check out the live menu $5 and $6 available ..
Death Bubba and Nukem At $12
There's been a lot of talk in the 21st century about legalizing marijuana for medical use while proper dosage has been an issue that has not gotten as much attention in the media. Canada has left the issue up to doctors whereas in the United States there's almost a sense that it's up to patients themselves. Doctors are learning, however, from the patients themselves, what level of dosage works with respect to the following factors.
If there were just one kind of cannabis plant, doctors would have a much easier time recommending a certain dosage. But the reality is that there are literally thousands of various cannabis strains around the world. Some strains are very potent while others do not have much effect on the mind or body. Additionally there are two separate components of cannabis that have medicinal value: the intoxicating THC chemical that is typically smoked and the non-intoxicating CBD chemical, which is often administered in liquid form.
Complicating the matter further is that eating cannabis can be much more potent and intoxicating than smoking cannabis. To some degree, you must decide as a patient what your limit of intoxication should be, since it varies among different individuals. For people who do not like the psychoactive effects of getting high, they should limit their serving of a marijuana brownie to a small square, perhaps the size of a few sugar cubes.
Other ways of ingesting cannabis can be through inhaling with a vaporizer and swallowing a capsule form that is manufactured by a pharmaceutical company. Proper dosage levels vary for each form of ingestion, as effects can be felt more quickly from smoking it than eating it while the effects of edible cannabis can last much longer. Experimentation should be gradual for new users.
Overall, scientists have found cannabis to have low toxicity without much concern about an overdose. It is more likely, for example, that a heavy user of cannabis will simply fall asleep if dosage is excessive. Unlike certain dangerous pharmaceutical drugs, cannabis appears to present not even a minor threat of fatal consequences. Exceptions might be for patients who suffer from heart problems, in which cannabis should simply be avoided, since it can affect heart rate.
Even though marijuana is not considered physically addictive, the more you use the drug the more tolerance you build, requiring stronger dosage to get the desired effect. While it can be psychologically habitual, casual users do not exhibit many side effects beyond dry mouth and red eyes. Taking a few puffs occasionally is all some people need for reducing stress and other dispositions.
Despite all the mysteries surrounding medical cannabis, proper dosage can be measured and over time, there will likely be more definitive standards for dosage. One of the few medical professionals who has published proper dosage amounts is Donald Abrams, MD. He is a Professor of Clinical Medicine at the University of California, San Francisco. He concluded that experienced cannabis smokers can regulate their own dosage in order to achieve the desired effect. He also offered "final dosing recommendations" based on the strength of THC.
For cannabis with 10 percent THC, Abrams suggests a daily dosage of between .15 to 5.55 grams. As the THC level increases for medical cannabis, proper dosage decreases in grams. Marijuana with 20 percent THC, for example, corresponds with a dosage of .08 to 2.79 grams while 30 percent corresponds with .01 to 1.86 grams. This dosage recommendation is similar to other low toxicity drugs.
Patients with legal access
to medical marijuana reduce their consumption of conventional pharmaceuticals, according to a demographic review of
patient characteristics published online in the Journal of
Investigators affiliated with the Medical Marijuana Research Institute in Mesa surveyed responses from 367 state-qualified patients recruited from four Arizona medical cannabis dispensaries. Respondents were more likely to be male, in their mid-40s, and daily consumers of cannabis.
Respondents most often reported using cannabis therapeutically to treat symptoms of chronic pain, muscle spasms, nausea, anxiety, arthritis, depression, headaches, insomnia, and stress. Patients typically said that cannabis provided “a lot of relief” or “almost complete relief” of their symptoms and that its efficacy was greater than that of more conventional medications.
Patients also reported reducing their use of pharmaceuticals. Over 70 percent of respondents reported using other medications “a little less frequently” or “much less frequently” for 24 of the 42 conditions specified. Over 90 percent of those who reported consuming cannabis to mitigate symptoms of nausea, headache, muscle spasms, fibromyalgia, bowel distress, and chronic pain acknowledged using pharmaceuticals less frequently once they had initiated cannabis therapy.
Previously published survey data of medical cannabis patients similarly report subjects’ willingness to substitute cannabis for prescription drugs, particularly opioids.
A study published in July by the National Bureau of Economic Research, a non-partisan think-tank, reported, “[S]tates permitting medical marijuana dispensaries experience a relative decrease in both opioid addictions and opioid overdose deaths compared to states that do not.” Data published in 2014 in the Journal of the American Medical Association (JAMA) Internal Medicine similarly reported, “States with medical cannabis laws had a 24.8 percent lower mean annual opioid overdose mortality rate compared with states without medical cannabis laws.”
Full text of the study, “Medical cannabis in Arizona: Patient characteristics, perceptions, and impressions of medical cannabis legalization,” appears in the Journal of Psychoactive Drugs.
Launching Special $35 instead of Reg. price at $45
Approx burn time 30 hours, really nice lemon smell,
chill around for 10 to 30 minutes to feel the calming and relaxing benefits.
Only 15 left in Stock at Broadway
regulating marijuana would help – not hurt – young people who suffer from mental illness or use the drug to self-medicate, say psychiatrists and addiction experts, who argue that is the only way
for the public to have an open dialogue on the harms associated with the illegal drug.
marijuana is quickly becoming a popular treatment for hundreds of thousands of patients for whom conventional treatments have failed
By 2013, Liz Gorman had lost hope. Her daughter Maddie, then 6, suffered from relentless seizures, untamed by 13 medications and even brain surgery. Maddie could barely fall and stay asleep, much less learn to read. Even waking up triggered seizures. Desperate, Gorman began weighing a treatment – a cannabis extract called Charlotte's Web – she'd never thought she would try. "I'm a conservative Republican, the wife of a major in the Marine Corps," she says. "It never dawned on me that this was the way to fix my child." Moreover, getting access to Charlotte's Web would mean leaving her husband and home in Raleigh, North Carolina, and moving Maddie to Colorado, where the extract is made and where in 2012 medical marijuana was legalized. In the end, willing to do anything to help her daughter, Gorman relocated to Colorado Springs in December 2013. She now gives Maddie one drop of Charlotte's Web oil twice each day and marvels at her improvement. Her seizure rate is down by 95 percent. "I hate to use the word miraculous," she says, "but for us, it really has been."
Federal law says marijuana is a controlled substance with a high potential for abuse and "no currently accepted medical use." But that hasn't stopped 23 states and the District of Columbia from legalizing varieties of cannabis – a genus that includes marijuana and hemp, which has therapeutic but not mind-altering properties. States have approved cannabis use for conditions as wildly dissimilar as epilepsy, chronic pain, the loss of appetite and nausea caused by chemotherapy, muscle spasticity associated with multiple sclerosis, diabetes, glaucoma and post-traumatic stress disorder. In some states, retailers are cautiously stocking their shelves with cannabis-based edibles, oils, mists, lotions, lip balms and flower buds. They're moving cautiously because federal law trumps state law, and while some members of Congress want to prevent the government from intervening, there's been no consensus on action yet. "There's legitimate fear in the marketplace that, if we go in and set up shop, we'll have the police on our backs," says Douglas A. Berman, professor of law at Ohio State University.
In March, several bills were introduced, the most ambitious a measure that would let states legalize marijuana for medical use without federal interference. Another bill would exclude Charlotte's Web from the list of controlled substances. Other measures would limit federal prosecutors' power to go after growers, vendors and users who obey state laws.
Meantime, as people like Gorman testify to the plant's effects, medical marijuana is rapidly becoming a go-to treatment for hundreds of thousands of patients for whom conventional treatments have failed. This is true despite the fact that research into the plant's benefits is worryingly thin. A sweeping review of the research done so far, published in the Journal of the American Medical Association in June, found that most studies have produced, at best, only "moderately" trustworthy evidence of effectiveness, mostly in patients undergoing cancer chemotherapy, people suffering chronic pain, and multiple sclerosis patients with pain and spasticity. The evidence was "poor" for many state-approved indications, such as hepatitis C, Crohn's disease, Parkinson's disease and Tourette syndrome, wrote psychiatrists Deepak Cyril D'Souza and Mohini Ranganathan of the Yale University School of Medicine in an accompanying editorial. Research on seizures is going on now. On the other hand, cannabis contains a potential pharmacopeia of more than 80 chemicals called cannabinoids and approximately 400 other compounds. "I do believe if we did the appropriate research, we would find some of those compounds have true medicinal value," says Otis Brawley, chief medical officer of the American Cancer Society.
The cannabinoid responsible for marijuana's mind-altering properties, delta-9-tetrahydrocannabinol or THC, was identified in the early 1960s along with the active ingredient in Charlotte's Web, cannabidiol, which lacks THC's trippy high. One explanation for medical marijuana's broad biological activity is that humans, like all other creatures, have innate cannabinoids that bind to receptors in the brain and immune system and play a critical role in growth and development, scientists say. Research in animals shows that if you block cannabinoid receptors in infancy, the animals will stop eating and die.
The receptors' location may offer clues to cannabinoids' perceived medical effects. One set of receptors is concentrated in nerve centers linked to pain perception, for example; a second set, mainly found in the immune system, may account for cannabis' potent – and well-established – anti-inflammatory properties. Scientists have found that cannabinoids act as a nervous system dimmer switch, slowing or blocking signals between nerve cells.
High concentrations of signal-blocking cannabinoid receptors throughout the brain may explain why cannabinoids appear to quell seizures. Receptors are similarly dense in regions that control movement, promote appetite and combat nausea, which may explain why marijuana seems to relieve muscle spasticity and boost appetite. Although cannabis has many side effects – dry mouth, bloodshot eyes, inceased appetite, diminished short-term memory, anxiety and impaired reaction time among them – no fatal overdose has ever been reported. That's likely due to the relative absence of cannabinoid receptors in the brain stem, the region that controls heart rate and breathing.
Some researchers believe that cannabinoids may actually treat cancer itself. In the lab, they stop cells from dividing and slow the spread of cancer cells into nearby tissues. And researchers in Spain and England have shown that cannabinoids can shrink brain tumors in animals. "Our animal work is very convincing indeed," says Stephen Wright, chief medical officer of GW Pharmaceuticals, a British firm that is developing cannabis-derived drugs. The company is now studying a drug in patients with recurrent brain cancer, Wright says, with results due next year.
Beyond the plant extracts, two drugs that are synthetic versions of THC, Marinol and Cesamet, are available by prescription across the U.S. Both were approved in 1985 to relieve nausea and vomiting in cancer patients. Marinol also has been shown to combat weight loss in people with HIV/AIDS. In addition, GW Pharmaceuticals has three pharmaceutical-grade cannabis medicines, including one, still unnamed, that is being tested in patients with Type 2 diabetes. Sativex, a mix of cannabidiol and THC, is approved in 28 countries for relieving spasticity and is being tested in the U.S. for its ability to relieve cancer pain.
The third drug, Epidiolex, made of cannabidiol only, is being tested in children with severe epilepsy whose seizures haven't responded to other drugs. Preliminary results in more than 130 children revealed that after 24 weeks of treatment, their average number of seizures had fallen by 45 percent, says neurologist Orrin Devinsky, director of the NYU Langone Comprehensive Epilepsy Center, who is leading the trial. In Colorado, neurologist Edward Maa, chief of the Comprehensive Epilepsy Program at Denver Health Medical Center, is taking advantage of the community using Charlotte's Web to closely monitor the experience of 150 seizure patients.
Maddie, now 8, is rapidly making the headway she couldn't when constantly having seizures. "She knows her ABCs now. She knows her colors and her shapes," says Gorman. "We plan to begin working on sight-words this summer."
The success of cannabis legalization across the United States
over the past several years has somewhat convinced the American public that the War on Weed is a dying animal. However, the latest national crimes
statistics published earlier this week by the FBI reveal
that law enforcement agencies are continuing to bust people for minor marijuana offenses at a rate significantly higher than arrests for other “epidemic” drugs.
While several studies have looked at the so-called “beneficial” effects of medical marijuana treatments, a new study has looked at the other side of the
Marijuana and pain treatment, very few negative effects
Dr Mark Ware (MD,MBBS MRCP MSc) is lead author and principle investigator of the research paper. He is a professor in the Faculty of Medicine at McGill Univeristy and repected researcher in study of pain© McGill University
Dr. Ware is the lead author and principle investigator of the study published in the Journal of Pain under the title, “Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)”
It is the first long term study of the safety of medical marijuana use by chronic pain sufferers and Dr Ware said although people were using medical marijuana as part of their therapy, there had been no examination of any harmful side-effects.
The study began in 2004 and ran to 2008, as the researchers began following 215 adult patients, with chronic non-cancer pain, who used medical cannabis, and compared them to a control group of 216 chronic pain sufferers who were not cannabis users. The study involved seven clinical centres with pain management expertise across Canada located in Fredericton, Halifax, London, Montreal, Toronto and Vancouver.
The pain sufferers were given a monthly supply of medical marijuana. The average use was about 2.5 grams per day, and it was either inhaled (smoked) taken orally (edible), or vaporized.
Both the marijuana users and the control group underwent regular medical tests, and also underwent lung function and cognitive testing, and were asked about their pain, mood, and adverse events, and quality of life over the one year of follow up. A number of the subjects underwent complete panels of blood tests for routine biochemistry, liver and kidney function, and selected hormone levels.
Dr Ware says adverse effects were anything the patients experienced that was unwanted, from a headache, nausea, to dizziness, somnolence, etc. to other much more serious incidents..
No serious negative effects
The study showed that while there were slightly more adverse events such as headache or dizziness compared to the control group, Dr Ward says these were to be expected in the case of someone using cannabinoids. The study showed that there was no greater risk of serious adverse events in the marijuana group compared to the control group. The study found no evidence of harmful effects on cognitive function, or in blood tests among cannabis consumers but they did report significant improvement in their levels of pain, symptom distress, mood and quality of life compared to control group using other pharmaceuticals to control pain.
However, Dr Ware, does add a qualification to the research findings. “It is important to note the limitations of the study,” he said. “Patients were self-selected, not randomized, and most were experienced users. So what we are seeing is that it appears to be a relatively safe drug when used by people who have already determined that it helps them. We cannot draw conclusions about safety issues of new cannabis users”.
Another qualifier is that the study used quality-controlled marijuana with a reliable 12.5 % THC content, whereas the THC (active ingredient) level in non-medical marijuana can vary widely with unknown effects.
The research concludes, “that the adverse effects of medical cannabis are modest and comparable quantitatively and qualitatively to prescription cannabinoids. The results suggest that cannabis at average doses of 2.5g/d in current cannabis users may be safe as part of carefully monitored pain management program when conventional treatments have been considered medically inappropriate or inadequate.
The study was funded by the Canadian Institutes of Health Research (CIHR).
The Research Institute of the McGill University Health Centre (RI-MUHC) is a world-renowned biomedical and healthcare research centre. affiliated with the Faculty of Medicine of McGill University, and is the research arm of the McGill University Health Centre (MUHC
Nice Strains at Granville Right Now
click read more to watch great picture of Green Goddess, Juicy-G and Papaya
A marijuana home grower works on a marijuana flower in Montevideo
Retail sales of the plant are slated to begin in June 2016.
Two companies have obtained licenses from the Uruguayan government to cultivate marijuana, the country's National Drug Board said Thursday.
"Twenty-two proposals were presented ... and two licenses for production and distribution were given out," Juan Andres Roballo, head of the National Drug Board, said at a news conference.
Roballo said the move represents a "fundamental step" toward the implementation of Uruguay’s landmark 2013 law legalizing marijuana, which at the time was heavily criticized by proponents of the drugs. Since then, three states in the United States have legalized the retail sale of marijuana.
The two companies, Simbiosis and Icorp, are expected to produce up to 2 tons of marijuana a year.
Marijuana sales in licensed pharmacies across Uruguay will begin in June 2016, with the price expected to be around US$1.20 per gram. According to Augusto Vitale, the president of the Institute for the Regulation and Control of Cannabis (IRCCA), that low price was set with an eye toward undermining the black market.
The measure legalizing marijuana was passed during the administration of left-president Jose Mujica and should have come already come into effect by now. However, current-President Tabare Vazquez, though coming from the same party as Mujica, was skeptical of the policy change back when it was first debated. "Marijuana causes as much damage, or even more, than tobacco," he said in 2012. He seems to have moderated his view, however. In March, he announced he was delaying implementation of the law, with the country’s chief drug regulator saying the purpose was to ensure the program was successful.
Supporters of legalization argue that state control over the production and distribution of marijuana can be an effective strategy to regulate its use and cut profits for drug cartels. The law passed in 2013 requires users to register with the government and limits their consumption to one ounce per month.
An Irish mother has launched an appeal to help her fund specialist medical marijuana treatment in the US for her baby who
has a potentially life-threatening condition.
Yvonne Cahalane, from Dunmanway in West Cork, said she needs to raise €35,000 to fund the treatment for her 21-month-son, Tristan, who has a very rare form of epilepsy which triggers severe seizures.
“We missed out on a place on a medical trial in Carolina because he was too young,” Yvonne said.
“But a neurologist in a hospital in Colorado has agreed to take him on. We would like to be there early in the new year, and we are starting him on a new medication soon to stabilise him for travel. We hope that one year in the States will be enough.”
Tristan was diagnosed late last year with Dravet Syndrome — a rare and severe form of epilepsy. He suffers up to 20 seizures a day, with some of the more severe seizures lasting up to an hour.
“It’s very difficult to watch — it’s like a ticking time bomb,” Yvonne said. “It’s fine when the seizures are happening because the adrenalin kicks in and you just do what you need to do to help him. It’s tough though when they’re finished.
“The nighttime seizures are the worst part. Some are quite violent. And it’s the really long seizures — that’s when you worry about the possible long-term damage to him,” she said.
The medication Tristan needs to keep his seizures under control — CBD oil and THCA, both derived from the marijuana plant — is available in the US.
The little boy, who has been nicknamed Mr T because of his brave outlook, has had to learn to walk and talk again as a result of his seizures.
“He is so resilient. Even when he wakes up after a 20-minute seizure, he will sit up, wobbly and disorientated, but he’ll still have this big smile and say ‘hi’.
“These are the little things we fear we’ll lose if we get a really big seizure. We’re very lucky he recovered so well and is receiving physio and speech and language therapy to help. But some days are better some worse. It’s intractable and medications don’t control his seizures for very long. We have gone through most meds at this stage. This won’t get better without help.”
Yvonne appealed on the Neil Prendeville Show on RedFM yesterday for help fundraising to cover their medical costs and living expenses. The medication Tristan needs to keep his seizures under control — CBD oil and THCA, both derived from the marijuana plant — is available in the US.
The oil would be administered orally in drop form as part of a technical and slow process overseen by a neurologist. It would then be absorbed into the receptors in Tristan’s brain in the hope it would control his seizures. The medication could take up to three weeks to kick in.
Yvonne’s husband, John, and their oldest son, Oscar, three, plan to stay in Ireland while Yvonne and Tristan travel to the US.
She called on the Government last night to introduce legislation “sooner rather than later” to allow for the wider prescribing of medicinal cannabis here.
Medical marijuana treatment, similar to that lined up for Tristan, has been trialled successfully in London’s Great Ormond Street, in the Netherlands and France.
You can donate online at www.gofundme.com/tristans-med-fund.
Compassion Club Society and 12 other area cannabis dispensaries are waiting
for clarification from Canada's federal government following a threat to call in the Royal Canadian Mounted Police (RCMP)—unless they close their
Really nice Ak-47 with some purple in it .. Hybrid sativa dominant only at Broadway location ..
Limited stock.. Hurry up
Today's special $35 1/8
VANCOUVER - The Canadian Medical Association
and the federal government apply a far more rigid standard to prescribing marijuana than other drugs, resulting in negative - or even deadly - consequences, say experts from the B.C. Centre for
Excellence in HIV/AIDS.
A number of Canada’s medical marijuana growers are poised to release
cannabis oils for authorized patients who don’t want to smoke or vaporize the dried herb to relieve their symptoms.
A new study by the University of British Columbia and University
of Victoria suggest that more people are using marijuana as a substitute for prescription drugs and alcohol because it’s less addictive.
As more and more
places legalize and regulate cannabis, the wider implications of bringing the trade above ground have inevitably attracted scrutiny. A growth in tourism related to the drug is one such
implication, and it's dividing opinion.
Medical marijuana producers are bracing for the possibility that Canadians could elect a new government this fall — a change that could accelerate the already breakneck pace of growth in the
burgeoning industry and usher in new players such as tobacco companies and pharmacy chains.
In an effort for the Federal Bureau of Investigation to continue
recruiting young people to work in their cyber crime division, the agency is being forced to unofficially relax its policies when it comes to the past experiences of some candidates with
A TIKUN OLAM
EMPLOYEE WALKS THROUGH ONE OF THE COMPANIES' CANNABIS GREENHOUSES LOCATED IN ISRAEL.
At first glance, Israel may not seem to be a country with the most potential
in cultivating a powerful cannabis industry. With strict religious laws and guidelines that govern the country, it would be easy to believe that marijuana is the last thing on the Israeli
Mike Zimmer, the Director of LARA in
Michigan, has taken the futures of children and their families into his hands, only to crush them, insult them, and put all of their lives in danger. I was in attendance on July
at the last autism hearing in Lansing when the panel was finally given the chance to make an informed vote of 4-2 in favor of Autism being added to the list of qualifying conditions for medical
I held our 4-year-old son Emery affectionately in my arms as I spoke in front of the panel of our experience over the last year and how it has changed us. We are able to give Emery cannabis because of his epilepsy diagnosis. I explained what it has done to reverse his autism impairment, to help him grow and to be happy, and for us to be able to live together in the same home. Before cannabis, we were going to have to live in separate homes on the same farmland together. Emery could not help but attack everyone around him constantly, including his younger siblings. Now, we happily spend entire days together and can hardly imagine the road we were headed down before Emery’s brain was allowed to work the way it is meant to because of cannabis.
We were at the hearing with other friends as well. These friends have been fighting this for over two years. They are parents, family, friends, attorneys, doctors, experts, and other activists. Parents with adult autistic children spoke to the panel as well. These parents have spent decades watching their children suffer as they refill endless bottles of dangerous pharmaceutical medications. They explained that from all of their research and everything they have seen, they believe that cannabis will work. They want to try it. Parents like Dwight Zahringer have seen that other children using cannabis are not only experiencing changes in behavior and sleep patterns, but are also becoming verbal for the first time. Like every parent, these are things that he wants deeply for his own son, who is mostly non-verbal at the age of three. The original petitioner Lisa Smith’s son Noah, who has been non-verbal his whole life, has just recently started talking at the age of six because of cannabis. Parents caring for children with an autism diagnosis shouldn’t have to wait another day to try a proven safe and effective medicine that is non-toxic and has never caused a death. This is especially true when it’s helping so many people already.
Mike Zimmer denied the petition despite the panel’s recommendation to add it to the qualifying list of conditions.
The panel is specifically designated by LARA to make the decisions regarding new conditions that should qualify for protection under the MMMA. They reviewed over seventy-five peer-reviewed articles with over eight hundred pages of scientific information relating to the paediatric use of cannabis for autism. Parents should be able to choose this medicine for their autistic children. Adults who are suffering should be able to qualify as well. But instead of passing this decision through so that families can finally find relief, healing, and new positive experiences, Mike Zimmer denied it. From the decision:
“This lack of scientific evidence is concerning … the petition fails to acknowledge the direct impact on children… .”
And Lt. Governor Brian Calley, who has an autistic child of his own, weighed in by saying “there are neither sufficient studies nor scientific trials demonstrating its clinical impact to justify approval at this time.”
Maybe what these guys need is over eight hundred pages of information on the dangers of using anti-psychotics, anti-depressants, anti-insomnia, and anti-anxiety medications on children just to help them cope or to control dangerous behaviors.
Zimmer writes that children with autism “without associated seizure disorders” are already eligible under the language of the MMMA. He implies that if there are no seizures, then the autism is not severe, with no clear definition for what severe autism is.
Let’s help him with that: autism is a word with six letters. That’s it. But children with an autism diagnosis, whether it is considered severe or not, have to see doctors to get that diagnosis. And there are reasons for seeing the doctors. Parents can’t just walk into a dispensary and get an autism diagnosis and a medical card. Children with these conditions have a neurologist and sometimes many other doctors that they see regularly to monitor their growth, behaviors, and intelligence. It feels like what Mike Zimmer is really saying is that he doesn’t trust the many compassionate doctors, attorneys, parents, experts, social workers and other professionals who work in this field. These are the people who spend time with autistic children and their families. They support this petition. Yet, he feels he has the right to make this decision for all of us.
He does not have that right.
He does not have the right to put a time limit on the lives of people or to force parents to separate siblings from each other when they can grow up together as friends, happily and peacefully. He doesn’t have the right to choose the number of children that are allowed to thrive and succeed in this world. In his Final Determination letter, he even makes it a point to rebut the claims that adding autism would cause a minimal increase in participation among minors.
Attorney Michael Komorn suggests:
This guy is the head of LARA, the agency that licenses these physicians, and he relies upon the argument that the doctors that we license can’t be trusted and will abuse the system. To follow his logic, his licensed physicians will treat autistic patients who they are not qualified to treat … The solution is that he can regulate this through the physicians and lay down rules and regulations. Instead he shuts it down.
None of this matters, of course. Every child with an autism diagnosis will benefit from using cannabis. This is clearly outlined in all of the peer-reviewed information that was included with the petition even aside from the hundreds, if not thousands, of miraculous stories from all across the country. These are stories of autism impairment being reversed, sometimes seemingly overnight, just from using low doses of cannabis oil or other forms of cannabis. Let’s make sure these people have all the information they need to make this right for us!
Motor symptoms have been at the centre of these studies, as they constitute the most visible and most debilitating disorders in relation with Parkinson’s disease.
As early as the eighties, cannabinoids have been shown to alleviate dystonia, dyskinesia, and akinesia, all of them motor symptoms which have been known to impact certain Parkinson’s patients. For instance, controlled doses of synthetic cannabinoids have been able to reduce dyskinesia in patients suffering from Parkinson’s disease or Parkinsonism for years by 30%. Incidentally, medicinal cannabis as well as cannabis extracts-based medications are already being used to treat general spasticity in the context of other conditions such as multiple sclerosis or Gilles de la Tourette’s syndrome.
Research focusing on the degeneration of brain cells and its resulting impact on cognitive capacities – which is the origin of the aforementioned motor symptoms – has also been relatively active, with a few breakthrough studies published during the previous decade. The neuroprotective properties of cannabinoids had already been proven on many occasions, and the impact it could have on Parkinson’s disease was confirmed as well . In 2004, a research laboratory injected rats with an agonist of Tetrahydrocannabinol (THC), one of the major psychoactive substances of cannabis, followed by the injection of a toxin triggering an animal version of Parkinson’s. Upon testing of these rats in parallel with a control group of healthy subjects, researchers observed that their brains were virtually indistinguishable. In a second series of tests, other rats were this time first injected with the toxin, then with the THC agonist, with positive results as well, especially when THC was combined with Cannabidiol (CBD), a non-psychoactive cannabinoid known for its medicinal properties. In human terms, the second test suggested that cannabinoids intake could slow down the progression of the disease for several years.
Despite numerous studies underlining the multiple benefits of cannabis on Parkinson’s, no palliative or curative treatment has been developed, partly due to the lack of availability of medicinal cannabis dedicated to research. This is why the aforementioned studies have so far been considered with relative caution, especially since it was observed that an excessive dose of cannabis could reverse its own effects and temporarily worsen some of the motor symptoms. These results were however partly linked to the relative inefficacy of clinical tests conducted with synthetic cannabinoids, as well as the lack of familiarity of the subjects tested with medicinal marijuana or cannabis extracts-based medication.
In order to bypass the legal restriction of cannabis being illegal in most countries these last two years, many observational studies were published, focusing on patients already self-medicating with cannabis. The tests measured their reaction to a “dose” of medicinal cannabis, once again with positive outcomes in regards to motor symptoms as well as non-motor symptoms. Patients participating to the study reported that a “dose” of cannabis could relieve them for a period of 2 to 3 hours.
Finally, in March 2014, researchers from Tel-Aviv managed to show results for 22 patients suffering from Parkinson’s Disease, whose symptoms, both motor and non-motor, were relieved following the use of cannabis. The medical team registered important fluctuations in pain, sleep, and several motor symptoms, namely tremor, rigidity and bradykinesia. In addition to these results being the first study showing cannabis relieving motor and non-motor symptoms alike, no adverse effects were observed following the intake of cannabis. It is likely that these recent advances will trigger a newfound enthusiasm from the medical community to pursue research in this direction, especially since large amounts of medicinal cannabis have been unlocked for research in the United States.
2014, Linda Morado received the most devastating news of her life – a diagnosis of Stage IV kidney cancer. It had metastasized to her lungs in two places. The month prior, Linda had also been
diagnosed with celiac disease and nutrient malabsorption issues. Despite these overwhelming challenges, Linda was determined to live.
Marijuana might bring about a revolution in the field of organ transplantation by delaying the rejection of incompatible organ. Pictured, a budtender displays various types of marijuana available to customers.
The days of cannabis consumers being relegated to dropping flowers into glass bowls and rolling joints for smoking are long gone. While this option is certainly still available to fans
of the culture, today’s fans of the culture are focusing onvaporizing concentrates,
which are special extractions that strive to isolate the plant’s resin-bearing trichomes from
the leaf matter and other undesirable matter. The trichomes contain all cannabinoids and terpenes and,
thus, are the essence of the plant, providing all medical and recreational (psychoactive) value.
“The benefit from smoking as a route of administration is instant action
and the ability of the patient to self titrate the dose needed for relief. Here we describe how patients can achieve similar quick acting relief and the ability to control dose without smoking.
It is important that the medical community understand that whole cannabis products are available today that provide significant relief without smoking. We don’t have to wait for a pharmaceutical
pill to be developed years in the future in order to have the benefits of cannabis. The present pill (Marinol) has proven very unsatisfactory due to a long delay of action time, poor absorption
in the GI tract, and its failure to include many of the antioxidant and anti-inflammatory cannabinoids present in whole cannabis and its extracts. In addition, future pharmaceuticals will be
wildly expensive. [Editor’s
note: Most importantly, side effects of Marinol include death,
with the FDA reporting 4
deaths directly related to Marinol, and one death indirectly related.]
Tinctures are not new. Until cannabis was banned in 1937, tinctures were the primary type of cannabis medicines. Tinctures are
essentially alcohol extractions of whole cannabis (usually the flowers and trim leaves). Tinctures are easy to make and very inexpensive. Tinctures contain all 80 of the essential cannabinoids
instead of only one with Marinol. Some of the cannabinoids such as cannibidiol (CBD) actually reduce the psychoactive effects of THC while increasing the overall efficacy of the
The best way to use tinctures is sublingually (under the tongue). Titration or dose control is easily achieved by the number of drops a patient places under the tongue where the medicine is rapidly absorbed into the arterial system and is quickly transported to the brain and body. All a patient need do with tincture is use a few drops, wait for the desired medical effects, and either use more or stop as the situation indicates. Tinctures can be flavored for better taste. They are best stored in dark bottles in the refrigerator. Since tinctures average some 75% ethanol there is little worry of bacterial or other biological contamination. Those who wish to avoid alcohol can instead use their tincture as a base for making a concentrated elixir. (recipe)” – viaSmokeless Medicine
In Sale in our Broadway Location at special price 35$
After decades of claiming that cannabis has no medicinal value, the U.S. government is finally admitting that cannabis can kill cancer cells.Although still claiming, the admission that highlights a rapidly changing perspective on medicinal cannabis treatments. In the most recent update to the National Cancer Institute’s (NCI) website included a listing of studies, which indicated anti-tumor effects of cannabis treatment..
Preclinical studies of cannabinoids have investigated the following activities:
• Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow. Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells.
• A study in mice showed that cannabinoids may protect against inflammation of the colon and may have potential in reducing the risk of colon cancer, and possibly in its treatment.
• A laboratory study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.
• A laboratory study of cannabidiol (CBD) in estrogen receptor positive and estrogen receptor negative breast cancer cells showed that it caused cancer cell death while having little effect on normal breast cells. Studies in mouse models of metastatic breast cancer showed that cannabinoids may lessen the growth, number, and spread of tumors.
• A laboratory study of cannabidiol (CBD) in human glioma cells showed that when given along with chemotherapy, CBD may make chemotherapy more effective and increase cancer cell death without harming normal cells. Studies in mouse models of cancer showed that CBD together with delta-9-THC may make chemotherapy such as temozolomide more effective.
The NCI, part of the U.S. Department of Health, advises that ‘cannabinoids may be useful in treating the side effects of cancer and cancer treatment’ by smoking, eating it in baked products, drinking herbal teas or even spraying it under the tongue.
The site goes on to list other beneficial uses, which include: anti-inflammatory activity, blocking cell growth, preventing the growth of blood vessels that supply tumors, antiviral activity and relieving muscle spasms caused by multiple sclerosis.
Several scientific studies have given indications of these beneficial properties in the past, and this past April the US government’s National Institute on Drug Abuse (NIDA) revised their publications to suggest cannabis could shrink brain tumors by killing off cancer cells, stating, “marijuana can kill certain cancer cells and reduce the size of others.”
“Evidence from one animal study suggests that extracts from whole-plant marijuana can shrink one of the most serious types of brain tumors,” the NIDA said. “Research in mice showed that these extracts, when used with radiation, increased the cancer-killing effects of the radiation.”
Research on marijuana’s potential as a medicine has been stifled for decades by federal restrictions, even though nearly half of the states and the District of Columbia have legalized medical marijuana in some form.
Although cannabis has been increasingly legalized by states, the federal government still classifies marijuana as a Schedule 1 drug — along with heroin and ecstasy — defining it as having no medical benefits and a potential for abuse.
The vast majority of the $1.4 billion spent on marijuana research, by the National Institute of Health, absurdly involves the study of abuse and addiction, with only $297 million being spent researching potential medical benefits.
Judging by the spending levels, it seems the feds have a vested interest in keeping public opinion of cannabis negative. Perhaps “Big Pharma” is utilizing their financial influence over politicians in an effort to maintain a stranglehold on the medical treatment market.
Read more at http://thefreethoughtproject.com/national-cancer-institute-finally-admits-cannabis-kills-cancer/#pQiXesHgAwzF5PFy.99
Read more at http://thefreethoughtproject.com/national-cancer-institute-finally-admits-cannabis-kills-cancer/#pQiXesHgAwzF5PFy.99
Chico Ryder was 11 years old when he was diagnosed with Stage III/Group III parameningeal embryonal rhabdomyosarcoma, an especially aggressive soft tissue cancer, in December 2012. He
began the long road to recovery and immediately began chemotherapy after diagnosis.
A new study shows that mutations associated with autism block the action
of brain molecules that act on the same receptors that marijuana’s active
chemical acts on.
A new study shows that mutations associated with autism block the action of brain molecules that act on the same receptors that marijuana’s active chemical acts on. Endocannabinoids are molecules that affect memory, learning, pain, and other important processes. They share a similar chemical structure with THC, the primary psychoactive component of marijuana. Endocannabinoids naturally occur in the human brain, and are responsible for synaptic signaling within the brain.
Thomas Sudhof, a cellular physiologist at Stanford University, tested mutations associated with autism in mice. Two mutations associated with autism in a synapse-adhesion protein led to deficits in prolonged endocannabinoid signaling in mice. This suggests that autism could caused by a disruption of the brain’s ability to send clear signals.
The researchers studied two mutations in neurologin-3 (NL-3), a gene encoding a protein that builds and maintains synapses. One mutation is a deletion of the entire gene, while the other, R451, contains a single amino acid substitution. Both of these mutations have been associated with autism in humans.
Sudhof and colleagues made electrophysiological recordings of the interactions between pairs of cells in the hippocampal areas of the mouse brains. They compared the brains of the mutated mice with those of normal mice. They found that cells containing cannabinoid type-1 (CB-1) receptors showed that tonic endocannabinoid signaling had been disrupted.
The researchers are not clear on why the mutations affect endocannabinoid signaling. They also do not yet understand how endocannibinoid signaling deficits are involved with the symptoms of autism. Their findings do, however, call for more research, which could lead to new and improved treatments for autism.
Another study by Danielle Piomelli of UC Irvine and Olivier Manzoni of INSERM, the French national research agency, treated mice exhibiting symptoms of Fragile-X Syndrome, a disorder that causes autistic symptoms, with novel compounds that correct the signaling of endocannibinoid transmitters in the brain. The mice showed dramatic behavioral improvements in maze tests measuring anxiety and open-space acceptance.
Do these findings suggest that www.alexneedshelp.com. It is too early to tell, but families who are already using the drug to treat their children’s symptoms believe it has made all the difference in the world. Many children with autism are already given cocktails of drugs that may be even stronger than marijuana, with serious side effects and limited results. Meiko Hester-Perez credits medical marijuana with saving her son’s life. He was dangerously underweight, with extreme anxiety and self-injurious behaviors. Alex Echols is another child who suffered from extreme rages with self-injurious behaviors, and his family writes about their success with medical marijuana on their family blog at
The researchers involved in these studies do not advocate giving medical marijuana to children with autism, but they do concede that these findings may lead to medications and treatments that can increase the natural endocannibinoids already found in the human brain. These treatments may also be useful for many other debilitating illnesses, including anxiety, pain, depression, and obesity.
PORTLAND, Ore. (Reuters) - Marijuana sales for recreational use
began in Oregon on Thursday as it joined Washington state and Colorado in allowing the sale of a drug that remains illegal under U.S. federal law.
Oregon residents 21 years and older can buy up to a quarter-ounce (seven grams) of dried pot at roughly 200 existing medical-use marijuana dispensaries as a new law took effect.
Backers hope the law will help curb a flourishing black market, but opponents say it heightens drug use and access by children.
About 40 people lined up outside the medical pot dispensary Shango in a strip mall near Portland International Airport for the chance to buy recreational pot one minute after midnight, when the changes went into effect.
"We came to be part of the experiment," said Juliano Hamana, 24, in line with his girlfriend.
"I'm worried about the 25 percent tax coming in January," he said, "but for a $10 gram that's only a bit over $2 more. I think it might be worth it for the quality."
Voters in Oregon and Alaska last year approved marijuana use and possession in state-regulated frameworks. Alaska's law took effect in February, but regulations for stores are still in the works. Pot shops created specifically for the recreational market, like those operating in Washington state and Colorado, are expected to start in 2016 in both Oregon and Alaska.
The District of Columbia has also legalized marijuana possession.
While marijuana use remains illegal for any reason under federal law, 23 states allow cannabis for medical purposes. Legalization measures will be on the ballot in Ohio in November and in other states in 2016.
In Oregon, possessing and growing pot became legal in July. Through 2015, sales of pot for recreational use will be untaxed, though that will likely change next year.
"You can get all the best strains from Oregon, which can make this into a top tourist spot," said Sue Vorenberg, editor of the Cannabis Daily Record.
Roughly 30 municipalities in Oregon have enacted bans to the sale of recreational pot, while others have sharply limited the nascent industry.
In Portland, the state's largest city, lawmakers on Wednesday approved limits on the recreational marijuana stores that will open there, such as a requirement they be no closer than 1,000 feet (305 meters) from a school.
Portland commissioners said they expected to take further steps to refine their rules for the industry.
A Canadian research team has completed a benchmark study that looks at the effects of cannabis when used in pain management.
The team was led by Dr. Mark Ware from the Research Institute
of the McGill University Health Centre in Montreal. The national multicentre study looked at the safety of medical marijuana use among patients suffering from chronic pain. They found that
patients with chronic pain who used cannabis daily for one year, when carefully monitored, did not have an increase in serious adverse events compared to pain patients who did not use cannabis.
The results of the study have been published online in The Journal of Pain.
"This is the first and largest study of the long term safety of medical cannabis use by patients suffering from chronic pain ever conducted," said Dr. Ware. "We found that medical cannabis, when used by patients who are experienced users, and as part of a monitored treatment program for chronic pain over one year, appears to have a reasonable safety profile."
As part of the Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS), that started in 2004, the researchers followed 215 adult patients, with chronic non-cancer pain, who used medical cannabis, and compared them to a control group of 216 chronic pain sufferers who were not cannabis users. The study involved seven centres with pain management expertise across Canada located in Fredericton, Halifax, London, Montreal (two sites), Toronto, and Vancouver.
Patients were given access to herbal cannabis containing 12.5 per cent THC from a licenced producer. The marijuana was dispensed through the hospital pharmacy at each site, and patients collected their supply every month after completing the necessary visits and tests. Participants underwent lung function and cognitive testing, were asked about their pain, mood, and quality of life over the one year of follow up.
A number of the subjects underwent complete panels of blood tests for routine biochemistry, liver and kidney function, and selected hormone levels. The average amount of cannabis used overall was 2.5 grams per day whether smoked, vaporized or taken as edibles.
"Our data shows that daily cannabis users had no greater risk than non-users (control group) to experience serious adverse events,'' added Dr. Ware. ''We found no evidence of harmful effects on cognitive function, or blood tests among cannabis consumers and we observed a significant improvement in their levels of pain, symptom distress, mood and quality of life compared to controls.''
However, researchers did report an increased risk of non-serious adverse effects from the medical marijuana. Participants reported headaches, nausea, dizziness, and respiratory problems associated with smoking the drug.
"It is important to note the limitations of the study," adds Dr. Ware. "Patients were self-selected, not randomized, and most were experienced users. So what we are seeing is that it appears to be a relatively safe drug when used by people who have already determined that it helps them. We cannot draw conclusions about safety issues of new cannabis users."
The study was funded by the Canadian Institutes of Health Research .
Master Kush at 7.50$ ,, Tuna at 10$ ,, Black God on the marley menu at 14$
Monday: PRIMO - $10 off - 1/8 of ........
Tuesday: Budder Day - $10 off - ..........
Wednesday: Shatter Day - $10 off - ....
Thursday: Any $12 strain
Friday, Saturday & Sunday: Weekend Special -
$ off & free.. - 1/8 of any $10 Strains for .....
If Canada's new government chooses to legalize marijuana beyond medical use
then it should get into the business of controlling its supply and sale to prevent the rise of a "Big Cannabis," addiction specialists say.
Cannabis policy could be an issue ahead of October's federal election. The governing Conservative party favours the status quo, the competing Liberals seek to legalize, regulate and tax, and the New Democrats support decriminalization. The Green Party has said it would legalize and tax marijuana.
In a commentary published in Monday's issue of the Canadian Medical Association Journal, addiction doctors describe the negative aspects of prohibiting cannabis use, such as fuelling the illegal drug trade and the high costs and harms associated with policing and prosecuting people.
"We're hoping to provide some direction to policy-makers in Canada to encourage them to rethink their current policies around cannabis, to move away from prohibition because it doesn't work and has a lot of harms associated with it," Dr. Sheryl Spithoff, a family physician and addiction doctor at Women's College Hospital in Toronto and one of the coauthors of the paper, said in an interview.
Often the harms from prohibition versus harms from potential increased use of cannabis are falsely pitted against each other, Spithoff and her team said. But cannabis prohibition has shown to have no effect on rates of use in developed countries.
"A frequently cited concern with legalization is that it will allow the rise of Big Cannabis, similar to Big Tobacco and Big Alcohol. These powerful multinational corporations have revenues and market expansion as their primary goals, with little consideration of the impact on public health. They increase tobacco and alcohol use by lobbying for favourable regulations and funding huge marketing campaigns. It is important that the regulations actively work against the establishment of Big Cannabis," the authors wrote.
They suggest that policy-makers draw on the extensive research on tobacco, alcohol and cannabis policy frameworks developed by public health researchers to create a Canadian approach that maximizes benefits and minimizes harm of the potentially addictive substance.
A 2013 UNICEF report found that the prevalence of self-reported cannabis use among youth aged 11, 13 and 15 in the preceding year was highest in Canada at 28 per cent. Findings in other countries included:
"Our hope with legalizing it is that less youth will have access to it," Spithoff said. "We'll be able to achieve our public health objectives, restricting access; limited hours that stores are open; and also young people won't have to go the illegal market to access cannabis. Especially for young adults, that's risky. It allows them to be exposed to other substances, more harmful substances."
In 2014, the Toronto-based Centre for Addiction and Mental Healthestimated enforcement of cannabis laws costs Canadians $1.2 billion a year.
Spithoff said the harms of prohibition to individuals include the criminal records of 500,000 Canadians because of cannabis possession, stigma around its use and barriers to medical marijuana treatment.
In the CMAJ paper, the authors also compare the experiences with marijuana policies in the Netherlands, Spain, Uruguay and three U.S. states, where cannabis is legal for recreational use.
For example, Spithoff said Uruguay has a model that could be adapted for use in Canada, because it puts public health first. In contrast, the Dutch model hasn't solved the "back door" illegal supply problem.
Uruguay has licensed producers and a government commission that purchases cannabis from growers. The government sells it to individuals through pharmacies. The commission has control over production, quality and prices and has the ability to undercut the illegal market. Uruguay has also set a cutoff for cannabis-impaired driving.
Canada legalized marijuana for medical use in 2001. Detailed rules for commercial production and use of medical marijuana were implemented in 2014.
At a marijuana dispensary in Toronto, the idea of legalizing recreational pot was met with skepticism.
While cannabis advocate Amy Brown welcomes some regulation, she disagrees that pot is a public health concern any more than tobacco or alcohol. She worries about what government control would mean for growing the plant.
"The word 'monopoly' is where I disagree. A monopoly means complete and utter control of this product," Brown said. "Maybe an advisory board would be beneficial so that moms and pops who are growing their own cannabis can still grow their own."
Rosin Tech seems to be the newest hype in the Vancouver cannabis community and is becoming a growing trend around North America.To put it simply, Rosin Tech is a premium grade solventless
concentrate made from the power of a magical device called....
EQUAL Clinical Research Initiative Will Gather Anonymized Patient Data on Effects of Medical Cannabis
, /CNW/ - Bedrocan Canada Inc. ("Bedrocan" or the "Company"), a subsidiary of Tweed Marijuana Inc. (TSXV: TWD) ("TMI" or "Tweed"), along with its sister company Tweed Inc., is
pleased to announce the launch of the EQUAL (Evaluation QUAlity of Life) study. The clinical research initiative is a multi-centre, non-interventional, un-blinded study to evaluate quality of
life in Canadian patients treated with medical cannabis.
TORONTO -- An Alberta mother whose daughter has severe epilepsy has travelled to Ontario for a medical marijuana prescription after the girl's doctor said
he was no longer allowed to provide permission to purchase the product.TORONTO -- An Alberta mother whose daughter has severe epilepsy has travelled to Ontario for a medical marijuana
prescription after the girl's doctor said he was no longer allowed to provide permission to purchase the product.
Vancouver police say they are not planning any raids on local pot dispensaries after Health Canada reportedly sent out letters warning operators they have two weeks to shutdown or face an RCMP crackdown.
"Our position on the marijuana stores has not changed," said a statement issued by Const. Brian Montague on Friday morning.
"We have a great relationship with the RCMP and work together often to tackle regional issues," he said.
"The RCMP have the authority to enforce the Criminal Code anywhere in Canada, but I doubt they have the desire to spend time, money, and reallocate resources to a city policed by the VPD."
On Wednesday Health Canada sent out letters to 13 illegal marijuana dispensaries and compassion clubs across the country, warning the RCMP could raid them if they do not stop advertising and selling marijuana immediately, even those in cities where local police have tolerated them.
The letters come after Vancouver City Council approved new regulations to license medical marijuana dispensaries. At the time federal Health Minister Rona Ambrose said the operations remained illegal and federal government remained committed to shutting them down.
"Further to the Minister of Health's announcement on August 1, 2015, the department took steps to proactively monitor all forms of marijuana advertising and promotion," a spokesperson for Health Canada told CBC News.
"On September 9, 2015, the department (Office of Medical Cannabis) sent 13 letters to organizations who were found to be illegally advertising the sale of marijuana.
"The letters require that all advertising activities with marijuana cease. If continued non-compliance is identified, the Department may refer the case to law enforcement agencies for appropriate action."
One of the operators who received the letter by email on Wednesday was Jamie Shaw with the B.C. Compassion Club in Vancouver.
Shaw says she was puzzled by the demand that the society stop advertising, which she said it does not do.
"The letter said something about advertising in the subject line, but then didn't actually explain it at all, and actually started talking about Bill [C-17], and basically said that we had to stop and cease and desist all advertising of cannabis products, which is not something that we do," said Shaw.
Lawyer Kirk Tousaw, who worked on the landmark Supreme Court of Canada ruling on cannabis extracts, calls the move unprecedented and inappropriate.
"I think it opens a giant can of worms, it's really doing an end-run around the elected officials in Vancouver as well as the Vancouver Police Department."
Police in Vancouver have generally adopted a hands-off approach to the marijuana dispensaries.
The state of Colorado, which is considered the forefather of the fully legal cannabis trade in
the United States, reportedly generated more tax revenue in the last fiscal year than what was raised from the sale of alcohol.
In order to get a glimpse into what drugs we do, law enforcement scientists do things like measure drug metabolites in wastewater.
begin growing marijuana for medicinal purposes, as the Andrews Government moves to legalise the use of cannabis oil in exceptional circumstances.
The Government received a Victorian Law Reform Commission report on how to go about making it legal, which will be tabled in Parliament in the next fortnight.
The state does not have the power to import the drug, leading to the likelihood it would need to be grown locally.
The Government made a pre-election promise to legalise medicinal cannabis oil for "exceptional circumstances".
Health Minister Jill Hennessey said medicinal cannabis oil could make a huge difference when other medicines did not work.
"I've met many parents whose use of medicinal cannabis has significantly changed the quality of life of their children — these are kids with severe epilepsy, and a range of other syndromes," she said.
"Those parents have been forced to choose between breaking the law or treating their children in a way that has been extremely effective for them.
"We want to end that choice, and that's why we asked the Law Reform Commission how we should go about legalising medicinal cannabis, not if we should."
The national policy manager at the Australian Drug Foundation, Geoff Munro, said he supported the idea
"I can't see there is a problem with manufacturing it locally," he said.
"It seems appropriate that Victoria could produce its own supply, after all Australia already produces opium poppies for the production of morphine in Tasmania.
"But obviously the cultivation would have to be quite secure. Access would have to be restricted."
He said poppies had proven to be one of the major drivers of Tasmania's economy, and it could provide a boost in Victoria.
Greens leader Greg Barber said he supported the move, but it would need co-operation from Canberra.
"You've got everything from the growing, the production, the prescribing and the consumption that all needs legal support, and much of that is covered under federal law," he said.
Mr Munro said the public was able to distinguish the difference between therapeutic and recreational use, but there would need to be very clear guidelines in place.
"We are in favour of Victorians and Australians having access to the best medical care, and if cannabis products can provide superior outcomes for people who are unwell and suffering various ailments we are in favour of [it]," he said.
"As long as we draw a distinction between medicinal and other uses.
"We can't see a problem, as long as the cannabis products are prescribed under medical supervision, the dosage is controlled and the outcomes are evaluated according to scientific trial."
While medicinal cannabis is legal in dozens of states in the United States and many European countries, Victoria would become the first Australian jurisdiction to permit its use.
Ms Hennessey said she could not outline an exact date when the changes would be introduced, but the Government would make good on its election promise.
"This is a matter of great complexity, and we need to look at all sorts of things like how do you get supply, what category of patients should get access, what regulation you put around it, how do we make sure it's not subject to abuse," she said.
"We want to make sure we do it in a way that is safe, effective and sustainable."
Few members of the medical community that have done their research will
be able to deny pot’s
ability to treat, and even prevent the progression of rheumatoid
arthritis, the issue on the table is how to administer it. The medical establishment continuously delays the acceptance of cannabinoid drugs, without batting an eye when powerfully
addictive opiates reach the market time and time
You've likely heard that regulating cannabis markets will lead to more
stoned drivers on the road. Although the evidence
in support of this claim is weak, it's repeated time and time again. So
we thought we would ask members of law enforcement from Washington State, where cannabis markets were legalized and regulated under Initiative 502 in November 2012, what they think of this